Narsoplimab-wuug (Yartemlea) — Coverage Criteria for TA-TMA
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Covers medical necessity and authorization criteria for narsoplimab-wuug (Yartemlea) IV infusion to treat hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in patients aged 2 years and older; applies to Blue Cross Blue Shield - North Carolina.
Added requirement that the patient must be post-hematopoietic stem cell transplant for clarity.
Removed requirement that diagnostic features must be from two or more time points within 14 days.
Removed requirement that the patient must be classified as high-risk.
Duration of approval for both initial and continuation criteria was increased to 12 weeks.
Added requirement in continuation criteria that the patient has not experienced unacceptable toxicity with the requested agent.
Maximum units updated to reflect change (Maximum Units = 8,880).
Removed medical record documentation requirement from TA-TMA trigger evaluation.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.